ZYTIGA

August 12, 2019September 4, 2019

Breast, Ovarian Cancer Therapy Seen to Delay to Progression in Advanced Prostate Cancers in Phase 3 Trial

News

Men with metastatic castration-resistant prostate cancer (mCRPC) given Lynparza (olaparib), a breast and ovarian cancer treatment, went a clinically meaningful longer time without disease progression or death compared to those given standard ... Read more

August 7, 2019August 26, 2019

Prostate Cancer Therapy Zytiga Makes WHO’s Essential Medicines List

News

Zytiga (abiraterone acetate), a kind of hormone therapy, has been added to the World Health Organization’s (WHO) Essential Medicines List for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Updated every ... Read more

July 22, 2019August 26, 2019

MSN Labs to Launch Generic Version of Zytiga in U.S. Following FDA Approval

News

MSN Labs, the parent company of Novadoz Pharmaceuticals, is launching a generic version of Janssen Pharmaceuticals’ approved therapy Zytiga (abiraterone acetate) in the U.S. market. Following its approval by the ... Read more

May 16, 2019

Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests

News

Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate), a study suggests. The findings were ... Read more

March 13, 2019March 13, 2019

Trial To Test Lynparza-Zytiga Combo Recruiting Men with Metastatic Castration-resistant Prostate Cancer

News

A Phase 3 trial is recruiting men to test a combination of Lynparza (olaparib) and Zytiga (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Named PROpel (NCT03732820), ... Read more

March 4, 2019March 4, 2019

Xtandi, Zytiga Better for African-Americans Than Whites With Advanced Prostate Cancer, Research Finds

News

African-Americans with metastatic castration-resistant prostate cancer live longer after treatment with the androgen inhibitors Zytiga (abiraterone acetate) or Xtandi (enzalutamide) than white men, a new study reports. Historically, African-Americans diagnosed ... Read more

January 10, 2019

Phase 2 Trial of Tomivosertib Begins Dosing Advanced Castration-resistant PC Patients

News

A Phase 2 clinical trial evaluating eFFECTOR Therapeutics’ investigational therapy tomivosertib (eFT508), for men with advanced castrate-resistant prostate cancer (CRPC) who failed to respond to androgen receptor signaling (ARS) inhibitors, has begun ... Read more

July 9, 2018

Prostreat Seen as Better Than Current Therapies at Stopping Aggressive Prostate Cancer in Mice

News

NucleoBio’s investigative therapy Prostreat was seen to be better at preventing the growth and spread of metastatic castration-resistant prostate cancer than currently available hormone therapies, a mouse study showed. The ... Read more

June 27, 2018June 27, 2018

Trovagene Begins Testing PCM-075 Plus Zytiga in Advanced Prostate Cancer Patients

News

Trovagene will soon begin patient recruitment for its Phase 2 clinical trial evaluating PCM-075 in combination with Zytiga (abiraterone acetate) and prednisone for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). The ... Read more

June 14, 2018

Zytiga Rejected in England as First-line Treatment for Newly Diagnosed Advanced Prostate Cancer

News

Janssen’s medication Zytiga (abiraterone) was recently rejected as a first-line treatment for newly diagnosed advanced prostate cancer on the National Health Service (NHS) in England following an initial draft recommendation from the National ... Read more